Moleculin Biotech, Inc. Deferred Tax Liabilities, Net
Moleculin Biotech, Inc. (MBRX) had Deferred Tax Liabilities, Net of $68.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-03-18
- 2025-12-31: Deferred Tax Liabilities, Net $68.00K.
- 2024-12-31: Deferred Tax Liabilities, Net $92.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $112.00K.
- 2022-12-31: Deferred Tax Liabilities, Net $86.00K.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $68.00K 10-K · filed 2026-03-18 |
| 2024-12-31 | $92.00K 10-K · filed 2026-03-18 |
| 2023-12-31 | $112.00K 10-K · filed 2025-03-21 |
| 2022-12-31 | $86.00K 10-K · filed 2024-03-22 |
| 2021-12-31 | $29.00K 10-K · filed 2023-03-22 |
| 2020-12-31 | $55.00K 10-K · filed 2022-03-24 |
| 2019-12-31 | $33.00K 10-K · filed 2021-03-24 |
| 2018-12-31 | $72.00K 10-K · filed 2020-03-19 |
| 2017-12-31 | $4.00K 10-K · filed 2019-02-21 |
| 2016-12-31 | $4.00K 10-K · filed 2018-03-28 |
| 2015-12-31 | $0.00 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |